<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171964</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446EDE06</org_study_id>
    <nct_id>NCT00171964</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions</brief_title>
  <official_title>Evaluation of the Efficacy and Tolerability of Zoledronic Acid in Combination With Radiotherapy in Patients With Advanced Osteolytic Bone Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the aim of this multicentric clinical study to assess the efficacy and tolerability of&#xD;
      zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone&#xD;
      lesions in terms of the reduction of pain and analgesic consumption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>weekly assessments during 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to pain reduction</measure>
    <time_frame>weeks 0, 12, 24, 36, 48 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of pain reduction</measure>
    <time_frame>weeks 0, 12, 24, 36, 48 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>weeks 0, 12, 24, 36, 48 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in parameters of bone turnover</measure>
    <time_frame>weeks 0, 12, 24, 36, 48 and 60</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pain</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>zoledronic acid + radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zoledronic acid every 4 weeks in combination with radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid in combination with therapy</intervention_name>
    <arm_group_label>zoledronic acid + radiotherapy</arm_group_label>
    <other_name>Zometa</other_name>
    <other_name>Zomera</other_name>
    <other_name>Aclasta</other_name>
    <other_name>Reclast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of at least one cancer-related bone lesion in cancer patients, confirmed by&#xD;
             X-ray, MRT or computer tomography&#xD;
&#xD;
          -  Severity of pain ≥ 5 on item 3 of the BPI which is caused by the bone lesion(s) and&#xD;
             requires radiotherapy&#xD;
&#xD;
          -  Adequate liver function - serum total bilirubin concentration less than 1.5 x the&#xD;
             upper limit of normal value&#xD;
&#xD;
          -  Expected survival time ≥ 6 months&#xD;
&#xD;
          -  If the patient is of child-bearing potential: negative pregnancy test at screening&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with an oral bisphosphonate for more than 3 months or more than 3&#xD;
             intravenous (i.v.) bisphosphonate applications&#xD;
&#xD;
          -  Bisphosphonate treatment within 6 months before study start&#xD;
&#xD;
          -  Previous radiotherapy of the painful areas to be irradiated. An initiation of&#xD;
             radiotherapy for the target area(s) up to 3 days at maximum prior to the first&#xD;
             infusion is allowed.&#xD;
&#xD;
          -  Skeleton-related complications (e.g., pathological fractures, orthopedic intervention&#xD;
             to treat or stabilize an osteolytic defect, spinal cord compression) during the last 3&#xD;
             weeks prior to the first infusion of trial medication.&#xD;
&#xD;
          -  Initiation of a new chemotherapeutic treatment regimen during the last 2 weeks prior&#xD;
             to the first infusion of trial medication&#xD;
&#xD;
          -  Abnormal renal function as evidenced by a calculated creatinine clearance &lt; 30&#xD;
             ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault&#xD;
             formula: CrCl = [140-age (years)] x weight (kg) {x 0.85 for female patients} [72 x&#xD;
             serum creatinine (mg/dL)]&#xD;
&#xD;
          -  Corrected (adjusted for serum albumin) serum calcium concentration &lt; 8.0 mg/dl (2.00&#xD;
             mmol/L) or ≥ 12.0 mg/dl (3.00 mmol/L).&#xD;
&#xD;
          -  Patients with clinically symptomatic brain metastases&#xD;
&#xD;
          -  History of diseases with influence on bone metabolism such as Paget's disease and&#xD;
             primary hyperparathyroidism&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Women of childbearing potential not on a medically recognized form of contraception&#xD;
             (i.e., oral contraceptives or implants, intrauterine device [IUD], vaginal diaphragm&#xD;
             or sponge, or condom with spermicide)&#xD;
&#xD;
          -  Current active dental problems including infection of the teeth or jawbone (maxilla or&#xD;
             mandibular); dental or fixture trauma, or a current or prior diagnosis of&#xD;
             osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after&#xD;
             dental procedures.&#xD;
&#xD;
          -  Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://link.springer.com/article/10.1007/s00066-011-1001-z</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Bone metastasis</keyword>
  <keyword>Analgesic consumption</keyword>
  <keyword>Cancer patients</keyword>
  <keyword>Cancer patients with painful bone metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

